Novogyne Pharmaceuticals (a.k.a. Vivelle Ventures LLC) is a women's health products company jointly owned by Noven and Novartis Pharmaceuticals. Novogyne's products include Vivelle-Dot®, the world's smallest estrogen patch and the most dispensed estrogen patch in the U.S., and CombiPatch®, the first combination HT patch approved in the U.S. Novogyne has 120 sales representatives targeting U.S. physicians who frequently prescribe estrogen therapy products.
Novartis AG is a world leader in pharmaceuticals and consumer health. In 2006, the Group's businesses achieved sales of USD 37 billion and a net income of USD 7.2 billion. The Group invested approximately USD 5.4 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 100,000 people and operate in over 140 countries around the world. Novartis has certain rights to Vivelle®, Vivelle-Dot®, Estalis® and Estradot® and is a joint owner (with Noven) of Novogyne Pharmaceuticals.
Shire
plc is
a global specialty pharmaceutical company with a strategic focus
on meeting the needs of the specialist physician and currently focuses
on developing projects and marketing products in the areas of central
nervous system (CNS), gastrointestinal (GI), and renal diseases.
Shire
has the exclusive global rights to Daytrana®, Noven’s
developmental once-daily methylphenidate transdermal system for Attention-Deficit
Hyperactivity
Disorder (ADHD), which was launched in the U.S. in June 2006. Noven
and Shire are also working together to develop a transdermal amphetamine
patch for ADHD, which is presently in pre-clinical development.
Procter & Gamble is
celebrating 165 years of providing trusted quality brands that make
every day better for the world’s consumers. It
markets nearly 300 brands in more than 160 countries around the world.
The Procter & Gamble community consists of nearly 140,000 employees
working in over 80 countries worldwide. P&G Pharmaceuticals is
part of Procter & Gamble's Health Care global business unit.
P&G Pharmaceuticals is focusing in the areas of endocrinology, cardiovascular
and musculoskeletal diseases as well as anti-infective therapies. Noven
has worked with P&G Pharmaceuticals toward development of new prescription
transdermal products in the area of Hypoactive Sexual Desire Disorder.
Endo Pharmaceuticals, Inc., a leader in pain management, has a right of first refusal with respect to our developmental fentanyl patch for chronic pain, and we are working together with Endo to develop new prescription patches that could extend our collaboration beyond that product.
Copyright © 2008 Noven Pharmaceuticals, Inc. All rights reserved.